Skip to content

STUDY OF THE DOUBLE POLYMORPHISM (THR 555ILE) AND (GLU568PRO) OF THE CORIN GENE AS A RISK FACTOR FOR ARTERIAL HYPERTENSION IN A POPULATION OF AFRICAN DESCENT IN GUADELOUPE

STUDY OF THE DOUBLE POLYMORPHISM (THR 555ILE) AND (GLU568PRO) OF THE CORIN GENE AS A RISK FACTOR FOR ARTERIAL HYPERTENSION IN A POPULATION OF AFRICAN DESCENT IN GUADELOUPE

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07330804
Acronym
HTAG-CORIN
Enrollment
370
Registered
2026-01-09
Start date
2025-01-16
Completion date
2026-08-31
Last updated
2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Blood Pressure

Keywords

double polymorphisme, Corin, natriuretic peptide, biomarker, Afro Caribbean

Brief summary

Cardiovascular disease (CVD) mortality is the leading cause of death in high-income countries (particularly the United States), accounting for 23.1% of all deaths It has been established over several decades that hypertension disproportionately affects African Americans, compared with Americans of European descent:Hypertension occurs more often, at an earlier age , with greater severity , and is associated with an approximately 3-fold higher probability of death .There is also poorer control of hypertension despit e similar treatment In African Americans, CVD morbidity and mortality are compounded by the higher prevalence of T2DM, obesity, CKD, stroke, and heart failure . Despite advances in the identification of risk factors and the availability of effective treatment in hypertension, CVD disparities, persist among African Americans and are expected to increase in the future, particularly in younger age groups. Although various environmental and social factors certainly contribute to these disparities, a genetic basis, involving numerous candidate genes, is most often asserted in the literature . One of these is the Corin gene (Pan et al, 2002) which codes for the Corin protein.The latter plays a pivotal role in cardiometabolic pathophysiology through its role in the activation of natriuretic peptides .Natriuretic peptides (ANP and BNP) have a major role in the regulation of blood pressure through their vasodilatory and diuretic action. They have a lusotropic action, inhibit the renin angiotensin system, and are involved in energy metabolism (increased lipolysis and insulin secretion). They also have an anti-fibrotic, anti-proliferative, anti-inflammatory and anti-thrombotic action.The Corin gene of 244109pb has many variants that produce an inefficient protein with the corollary of the appearance of metabolic and cardiovascular pathologies in the first rank of which the HTA, the cardiac insufficiency and the renal insufficiency .Recently, a double polymorphism of the Corin gene consisting of 2 SNPs (single nucleotide polymorphisms) on the same allele of the Corin gene (I555/P568) has been reported. This allele is present in the heterozygous state in 12% of African Americans but is extremely rare in Americans of European descent (\<0.5%).This double polymorphism (I555/P568) has been shown to be responsible for an approximately 70% reduction in the ability of the mutated Corin protein to convert proANP or proBNP to the active form. In addition, the I555(P568) allele of Corin protein is associated with an increased risk of hypertension and concentric cardiac hypertrophy The corin allele (I555/P568) is reported to be associated with poorer response to validated heart failure therapy and a higher risk of death or hospitalization for heart failure . In Guadeloupe, where the population is predominantly of African descent.Cardiovascular disease is the leading cause of mortality.The prevalence of hypertension is 39% and more than 50% after 50 years of age . It has increased by 10% in 10 years in Guadeloupe. In France, where the prevalence of hypertension is 31%, it has increased by only 5% over the same period. Heart failure is the main cause of admission to the cardiological emergency room of the University Hospital (49%) with a mortality of 37% at 6 months. Hypertension is the first risk factor associated with heart failure (80%).To date, there are no studies on corin gene polymorphisms in Guadeloupe. Following the example of work already done in the African American population, we propose to study the role of the double polymorphism (I555/P568) in the determinism of hypertension in the population of African descent in Guadeloupe.

Interventions

DIAGNOSTIC_TESTdouble polymorphism

diagnostic test

Sponsors

Centre Hospitalier Universitaire de la Guadeloupe
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Case inclusion criteria * Persons affiliated with or benefiting from a social security plan; * Over 18 years of age; * Considering themselves to be of Afro-Caribbean descent; * Having given their free, informed, written and signed consent (at the latest on the day of inclusion and before any examination required by the research); * Treated for hypertension or presenting with hypertension according to recommendations: elevated blood pressure (BP), including systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg measured in the physician's office and confirmed over several visits on the day of inclusion or diagnosis made by ABPM or self-measurement. Control inclusion criteria: * Individuals affiliated with or benefiting from a social security plan; * Over 18 years of age; * Patients who consider themselves of Afro-Caribbean origin, of the same sex as the cases and ± 5 years of age, not treated for hypertension and not presenting with hypertension according to the HAS recommendations on the day of the inclusion visit. Controls will be recruited by the same GPs who included a person with hypertension, consulting for any other symptom * Having given their free, informed, written and signed consent (at the latest on the day of inclusion and before any examination required by the research);

Exclusion criteria

* Minors; Pregnant or breastfeeding women; Protected persons, or persons under court protection; Refusal to participate. Patients unable to come to the laboratory

Design outcomes

Primary

MeasureTime frameDescription
double polymorphismAt day 151. Genotyping by capillary electrophoresis (Sanger sequencing): 2. Genotyping using the allelic discrimination method

Secondary

MeasureTime frameDescription
Renal failureAt Day 15Frequency of renal failure in cases and
natriuretic peptid (NT PRO BNP)At Day 15natriuretic peptid assay in cases and controls
créatinine clearanceAt Day 15creatinine clearance in MDRD in cases and controls
Fasting blood glucoseAt Day 15Hb1AC measurement
CholesterolemiaAt Day 15measurement
triglyceridemiaAt Day 15measurement
Body Mass IndexAt inclusionBody mass Index calculation measurement in cases and controls
waistAt inclusionwaist circumference measurement in cases and controls
heart failureAt inclusionFrequency of heart failure in cases and controls
ECG measurements CornellAt inclusion, or month 3 for case and month 12 for controlmV
diastolic function E/ea ratioAt inclusion, or month 3 for case and month 12 for controlratio
parietal thicknessAt inclusion, or month 3 for case and month 12 for controlmm
left atrial size and volumeAt inclusion, or month 3 for case and month 12 for controlml
ECG measurement LewisAt inclusion, or month 3 for case and month 12 for controlmV
ECG measurement Sokolow-LyonAt inclusion, or month 3 for case and month 12 for controlmV
ECG measurment SiegelAt inclusion, or month 3 for case and month 12 for controlmV
ECG measurment RobertsAt inclusion, or month 3 for case and month 12 for controlmV
Left ventricular ejection fraction (LVEF)_systolic function in SimpsonAt 3 months for case, 12 months controlpourcentage

Countries

Guadeloupe

Contacts

Primary ContactHEDREVILLE SEGO, Doctor
hedrevillesego.cabinet@orange.fr+590 590 386355

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026